News about Market

Philogen Resubmits EMA Marketing Application for Melanoma Therapy Nidlegy with Updated Phase 3 Data

Philogen has resubmitted its EMA marketing application for investigational melanoma therapy Nidlegy, supported by updated Phase 3 clinical data demonstrating reduced risk of relapse or death and an extended patient follow-up period.

Market | 28/07/2026 | By News Bureau |  158

Harbour BioMed and Sinopharm Partner to Advance Research and Development

Harbour BioMed and Sinopharm have partnered to establish an innovation Research and Development (R&D) consortium focused on biologics for oncology and immune-mediated diseases.

Market | 28/07/2026 | By News Bureau |  129

Biodeal Pharmaceuticals Concludes Piramal Alternatives Partnership

Biodeal delivered strong revenue growth during the hold period, with EBITDA margins improving alongside continued investment in manufacturing and governance.

Market | 28/07/2026 | By News Bureau |  127

Senores Pharmaceuticals Q1 FY27 Revenue Grows 35.9 Percent YoY to INR 180.2 Crore

Senores Pharmaceuticals reported 35.9 percent Year over Year (YoY) revenue growth to INR 180.2 crore in Q1 FY27, driven by regulated and emerging markets and higher profitability.

Market | 27/07/2026 | By News Bureau |  160

CHMP Recommends EU Approval for NewAmsterdam Pharma's Obicetrapib Therapies to Treat High Cholesterol

NewAmsterdam Pharma and Menarini have received a positive CHMP opinion for Ubeslo and Evlarco, bringing the oral obicetrapib-based therapies one step closer to EU approval for patients with hypercholesterolaemia and mixed dyslipidaemia.

Market | 27/07/2026 | By News Bureau |  191

argenx to Acquire Forte Biosciences

argenx will acquire Forte Biosciences to add the first-in-class anti-CD122 antibody FB102, expanding its immunology pipeline.

Market | 27/07/2026 | By News Bureau |  172

EMA Backs Marketing Authorisation for Janssen's Icotyde in Plaque Psoriasis

CHMP backs marketing authorisation for icotrokinra to treat moderate-to-severe plaque psoriasis in adults and eligible adolescents, potentially making it the first oral IL-23-targeting therapy approved in the EU.

Market | 27/07/2026 | By News Bureau

Bluesight and Pfizer Partner to Expand RFID-Tagged Medications for Hospitals

Bluesight and Pfizer are bringing source-tagged Radio Frequency Identification (RFID) SmartDose medications to hospital pharmacies, streamlining inventory management and reducing manual tagging.

Market | 24/07/2026 | By News Bureau

Sun Pharma Acknowledges Organon Shareholder Approval for Acquisition

Sun Pharma has acknowledged Organon shareholders' approval of the proposed acquisition, marking a key milestone toward completion of the transaction.

Market | 24/07/2026 | By News Bureau |  209

Johnson & Johnson's Ottava Robotic Surgical System Receives US FDA De Novo Authorization

Johnson & Johnson receives US FDA De Novo authorization for the Ottava Robotic Surgical System, the world's first table-integrated soft tissue robotic platform, expanding access to robotic-assisted surgery across multiple general surgery procedures.

Market | 24/07/2026 | By News Bureau |  111